Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of LN003 for injection in metastatic castration-resistant prostate cancer
CTR20261437Phase 2Active
- Sponsor
- Shanghai Huiyong Pharmaceutical Research
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of LN003 in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Shanghai Huiyong Pharmaceutical Research. Started Apr 2026; status: active.
02
Drugs
LN003
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on CTR20261437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261437.